Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Revision History For: Protein Design Labs (PDLI): Stock strong

No earlier versions found for this Subject.

Return to Protein Design Labs (PDLI): Stock strong

I have been following this company for several years. Its stock price has done extremely well on good news on their humanized monoclonal antibody technology. Recently reported Phase III trial on Zenapax, which is used in kidney transplants. Results were favorable and filings for application will proceed this year. Although no earnings, their revenues are growing and have $100 million cash. Although they have had their share of disappointments, the basic technology appears to be sound. Another positive report had to do with using a beta isotope hooked up with a PDLI humanized antibody for cancer treatment.